Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Maze Therapeutics (MAZE) Gains from Investment Securities (2025 - 2026)

Maze Therapeutics' Gains from Investment Securities history spans 2 years, with the latest figure at $6.1 million for Q1 2026.

On a quarterly basis, Gains from Investment Securities rose 15.11% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.1 million, a 15.11% increase, with the full-year FY2025 number at $308350.0, changed N/A from a year prior.
Gains from Investment Securities hit $6.1 million in Q1 2026 for Maze Therapeutics, up from $308350.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for MAZE hit a ceiling of $6.1 million in Q1 2026 and a floor of $308350.0 in Q4 2025.